It's not very confidence inspiring to pull your guidance, and because of that we're looking hard at our 2006 estimates.
For investors in Pfizer, this is a meaningful event. This risk has been a significant overhang for some time.
We knew 2003 was going to be a challenge, but it appears it's going to be more of a challenge than we expected.
We had heard some investors were expecting a much worse forecast for next year, and those fears have been allayed.
The big drug companies are under duress on almost every front. There are challenges everywhere from generics, from the FDA, from managed care and from self-appointed public watchdogs criticizing the industry, and with attacks on direct-to-consumer advertising.
It'll be a challenge for [Takeda] by themselves, ... Lilly has historically had a very good presence in the diabetes area. But [Takeda] has got a good drug.
Even though there may be some good drugs available, it may take some time until they are more widely accepted.
We believe that some [PAH] patients are already using the active ingredient for pulmonary arterial hypertension.
Pfizer is clearly a winner here. Pfizer is clearly putting their solid foot forward. They've got a good franchise and it's good potential for the next couple years.
Copyright © 2024 Electric Goat Media. All Rights Reserved.